- Report
- April 2025
- 200 Pages
Global
From €2266EUR$2,490USD£1,943GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- January 2022
- 60 Pages
Global
From €1365EUR$1,500USD£1,170GBP
- Report
- April 2018
- 195 Pages
Global
From €13647EUR$14,995USD£11,699GBP
- Report
- March 2021
- 48 Pages
Global
€20022EUR$22,000USD£17,165GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €455EUR$500USD£390GBP
Forteo is a drug used to treat osteoporosis, a condition characterized by low bone density and increased risk of fractures. It is a recombinant human parathyroid hormone (PTH) analog, which stimulates new bone formation and increases bone mineral density. It is used to treat postmenopausal women, men with osteoporosis, and those with glucocorticoid-induced osteoporosis.
Forteo is part of the Endocrine and Metabolic Disorders Drugs market, which includes drugs used to treat conditions such as diabetes, obesity, and thyroid disorders. These drugs are used to regulate hormones and metabolism, and can be administered orally, intravenously, or topically.
Companies in the Forteo market include Eli Lilly, Novartis, Merck, and Pfizer. Show Less Read more